FDA approves revised medication guide for Coumadin

Share this article:
The FDA has approved a revised medication guide and labeling for Bristol-Myers Squibb's blood thinner Coumadin (warfarin sodium) to more prominently emphasize a warning about the risk of major or fatal bleeding.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions